Clovis肿瘤药物

CLVS NASDAQ
5.60
+0.40
+7.69%
盘后: 5.60 0 0.00% 17:58 08/16 EDT
开盘
5.46
昨收
5.20
最高
5.85
最低
5.45
成交量
579.96万
成交均量(3M)
262.70万
52周最高
37.27
52周最低
4.980
换手率
10.61%
市值
3.06亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Clovis肿瘤药物 CLVS股票价格,Clovis肿瘤药物股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).
展开 >

最近浏览

名称
价格
涨跌幅